Market Snapshot
S&P Futures
3,819
Dow Futures
30,822
Nasdaq Futures
11,785
Akouos, Inc. (AKUS) stock declined over -4.62% intraday to trade at $3.30 a share on NASDAQ. The stock opened with a gain of 8.20% at $3.47 and touched an intraday high of $3.59, falling -4.62% against the last close of $3.46. The stock went to a low of $3.21 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-07-06 | $3.47 | $3.59 | $3.21 | $3.3 | 181,646 |
2022-07-05 | $3.05 | $3.75 | $3.05 | $3.46 | 275,400 |
2022-07-01 | $4.61 | $4.81 | $2.91 | $3.11 | 976,000 |
2022-06-30 | $5.03 | $5.13 | $4.32 | $4.69 | 404,800 |
2022-06-29 | $4.79 | $7.15 | $4.75 | $5.2 | 11,139,600 |
2022-06-28 | $4.45 | $4.98 | $4.25 | $4.89 | 156,000 |
2022-06-27 | $3.9 | $4.56 | $3.67 | $4.44 | 112,600 |
2022-06-24 | $4.29 | $4.95 | $3.69 | $3.97 | 3,210,000 |
2022-06-23 | $3.75 | $4.22 | $3.71 | $4.21 | 132,800 |
2022-06-22 | $3.52 | $4.05 | $3.425 | $3.75 | 143,900 |
Employees-
Beta-
Sales or Revenue0
5Y Sales Change-
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryBiotechnology
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Akouos, Inc. (NASDAQ: AKUS) stock price is $3.3 as of the last check on Wednesday, July 6. During the trading session, AKUS stock reached the peak price of $3.59 while $3.21 was the lowest point it dropped to.
The NASDAQ listed AKUS is part of Biotechnology industry that operates in the broader Health Care sector. Akouos, Inc. , a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals.
Dr. Emmanuel Simons M.B.A., Ph.D.
Co- Founder, Pres, CEO & Director
Ms. Sachiyo Minegishi
CFO, Treasurer, Assistant Sec. & Principal Accounting Officer
Ms. Jennifer Anne Wellman M.S.
Chief Operating Officer
Dr. Michael John McKenna M.D.
Co-Founder, Chief Medical Officer & Member of Scientific Advisory Board
AKUS stock traded closed the last session at $3.3, which is $-0.16 or -4.62% lower than its previous close of $3.46. AKUS's current trading price is 42.55% lower than its 52-week high of $13.69 where as its distance from 52-week low of 2.32% is -75.89%.
Number of AKUS employees currently stands at -. AKUS operates from 645 Summer Street, Suite 200, Boston, MA 02210, United States.
Official Webiste of $AKUS is: https://www.akouos.com
AKUS could be contacted at AKUS operates from 645 Summer Street, Suite 200, Boston, MA 02210, United States, or at phone #857 410 1818 and can also be accessed through its website.
AKUS stock volume for the day was 181,768 shares while in the previous session number of AKUS shares traded was 181,646 . The average number of AKUS shares traded daily for last 3 months was 403.29 Thousands.
The percentage change in AKUS stock occurred in the recent session was -4.62% while the dollar amount for the price change in AKUS stock was $-0.16.
In the recent session, the day high for AKUS stock was $3.59 while the low for AKUS stock touched on the day was $3.21.
The market value of AKUS currently stands at 172.33 Million with its latest stock price at $3.3 and 34.53 Million of its shares outstanding.